Clinical Trials Directory

Trials / Completed

CompletedNCT01786876

Adsorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled SPD557 in Volunteers

A Phase 1 Study to Investigate the Absorption, Metabolism and Excretion of [14C]SPD557 Following a Single Oral Dose in Healthy Male Subjects

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
6 (actual)
Sponsor
Shire · Industry
Sex
Male
Age
18 Years – 50 Years
Healthy volunteers
Accepted

Summary

Phase I study to evaluate the excretion of radioactivity, the metabolic profile, pharmacokinetics, safety and tolerability following a single oral administration of \[14C\] SPD557 in healthy male volunteers aged 18 to 50 years (inclusive).The purpose of this study is to investigate how and how quickly SPD557 or its break down products are excreted by analysing blood, faeces and urine samples collected during the study.

Conditions

Interventions

TypeNameDescription
DRUGRadiolabeled SPD557A single oral dose of 2 mg radiolabeled SPD557 administered on Day 1

Timeline

Start date
2013-03-07
Primary completion
2013-04-12
Completion
2013-04-12
First posted
2013-02-08
Last updated
2021-06-10
Results posted
2014-03-27

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01786876. Inclusion in this directory is not an endorsement.

Adsorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled SPD557 in Volunteers (NCT01786876) · Clinical Trials Directory